Hepion Pharmaceutical's Lead Drug Shows Antifibrotic Effects In Animal Studies

Hepion Pharmaceuticals Inc HEPA has announced positive results from an in vivo study of CRV431.

  • In this study, the mouse model was treated for eight weeks with oral dosing of CRV431, or two comparator drugs, obeticholic acid, and elafibranor.
  • Fibrosis was reduced by 47% with CRV431, 35% with obeticholic acid, and 37% with elafibranor, relative to vehicle controls.
  • The company says that the results highlight a relatively short course of CRV431 treatment that can exert beneficial effects at an advanced stage of liver disease.
  • Price Action: HEPA shares trading 0.89% higher at $2.12 in market hours on the last check Tuesday.
Loading...
Loading...
HEPA Logo
HEPAHepion Pharmaceuticals Inc
$0.1689-46.9%

Stock Score Locked: Edge Members Only

Benzinga Rankings give you vital metrics on any stock – anytime.

Unlock Rankings
Edge Rankings
Momentum
N/A
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs

Comments
Loading...